Predicting response and toxicity to immune checkpoint inhibitors in lung cancer using antibodies to frameshift neoantigens

Table 5 Performance matrix of predictive model for irAEs

	Predicted symptomatic irAE	No predicted symptomatic irAE
Observed symptomatic irAE	14	4
No observed symptomatic irAE	2	40

ISSN: 1479-5876